Establishment of A2B5+/CD133– Glioma Stem Cell Line

Abstract: This study introduces the method of establishing A2B5+/CD133– glioma stem cell line to serve as a foundation for the basic research and clinical trial of targeted therapy against glioma stem like cells. Isolated from the specimens obtained from a male patient who suffered from glioma recurrence， the glioma cells were cultured for 10 generations (SHG-140)， after which the A2B5+/CD133– subgroup cells were separated and cloned to another cell line (SHG-ZW) and further transferred to stem cell line (SHG-ZWs). Immunohistochemical staining indicated that SHG-ZWs cell line with positive A2B5， nestin and Sox2 and negative CD133 expression was successfully established. Self-renewability and potential to differentiate into oligodendrocytes， astrocytes and neuron cells was reflected by secondary sphere forming test. The tumorigenicity and metastatic potential of SHG-ZW and SHG-ZWs cells were assessed through intracranial transplantation into brain tissue of 30 female Balb/SCID mice， and the immunohistochemical staining of pathological sections from harvested specimen indicated much more aggressive biological behavior of SHG-ZWs xenograft tumors when compared with those of SHG-ZW. In summary， the cell line SHGZW is a fast growing malignant cell line with positive A2B5 expression while SHG-ZWs is a GSC subgroup which express A2B5 with CD133 being absent. We hope that we could build a stable and effective way to establish A2B5+/CD133– glioma cell lines from fresh tumor tissues， which may contributes to further research of glioma.

CSTR: 32200.14.cjcb.2018.07.0005